Not all mR­NA vac­cines are cre­at­ed equal. Does it mat­ter?; Neu­ro is back; Pri­vate M&A af­fair; and more

Wel­come back to End­points Week­ly, your re­view of the week’s top bio­phar­ma head­lines. Want this in your in­box every Sat­ur­day morn­ing? Cur­rent End­points read­ers can vis­it their read­er pro­file to add End­points Week­ly. New to End­points? Sign up here.

As part of our broad­er and deep­er dri­ve, End­points has been pair­ing we­bi­na­rs with our spe­cial re­ports to cov­er more an­gles on a giv­en top­ic. In con­junc­tion with Max Gel­man’s neu­ro­science fea­ture, Kyle Blanken­ship mod­er­at­ed an in­sight­ful pan­el to dis­cuss where the field is head­ed. You can reg­is­ter to watch it on de­mand here.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER